In silico prioritization of potential matrix metalloproteinase-13 inhibitors for cartilage degeneration in knee injury-associated osteoarthritis.
4 affiliations
- 1Department of Orthopedics, Fuzhou University Affiliated Provincial Hospital South Branch, Fuzhou, China.
- 2Department of Otolaryngology, Fuzhou University Affiliated Provincial Hospital, Fuzhou, China.
- 3Department of Nursing, Fuzhou University Affiliated Provincial Hospital, Fuzhou, China.
- 4Department of Orthopedics, Fuzhou University Affiliated Provincial Hospital, Fuzhou, China. [email protected].
Abstract
Knee trauma is an important risk factor for post-traumatic osteoarthritis (PTOA), a progressive joint disease characterized by articular cartilage degeneration and limited disease-modifying treatment options. Matrix metalloproteinase-13 (MMP-13/collagenase-3) contributes to cartilage extracellular matrix degradation through cleavage of type II collagen, making it a relevant molecular target for cartilage-protective drug discovery. This study aimed to identify and prioritize potential small-molecule MMP-13 inhibitors using an integrated in silico workflow. The workflow included MMP-13 sequence retrieval, structural characterization, pharmacophore-based screening, molecular docking, ADMET/toxicity prediction, protein-ligand interaction analysis, protein-protein interaction and co-expression network analysis, and 100 ns molecular dynamics simulation. Among the screened compounds, P4C-BM was prioritized as an early-stage computational lead candidate based on its combined docking score, predicted ADMET profile, interaction pattern, and molecular dynamics stability. However, the findings are preliminary and computational only. The present study does not experimentally demonstrate direct MMP-13 inhibition, selectivity against other MMP family members, cartilage repair, clinical efficacy, or synergy with platelet-rich plasma, physiotherapy, or other treatment modalities. Among the screened compounds, P4C-BM was prioritized as an early-stage computational lead candidate based on its combined docking score, predicted ADMET profile, interaction pattern, and molecular dynamics stability. However, the findings are preliminary and computational only. The present study does not experimentally demonstrate direct MMP-13 inhibition, selectivity against other MMP family members, cartilage protection, cartilage repair, disease modification, or clinical efficacy. Therefore, P4C-BM should be regarded only as a candidate for further experimental validation in enzymatic assays, chondrocyte models, cartilage explant studies, and in vivo osteoarthritis or post-traumatic osteoarthritis models. No practice-related or treatment recommendations can be made from the present data.
Related
- A novel target associated with senescence and inflammatory signaling in human intervertebral disc degeneration
- Synovial SLC1A5-Associated Amino Acid Metabolic Features in Knee Osteoarthritis: An Integrated Analysis of Synovial Transcriptomics, Fecal Metabolomics, and Gut Microbiota
- HDAC Inhibitors Potentiate Doxorubicin Cytotoxicity in HepG2 Cells and Alter DNA-Repair- and p53-Associated Transcriptional Programs
- Investigating the anticancer potential of phytochemicals from the mangrove Rhizophora mucronata as inhibitors of lung cancer-associated proteins: Insights from multiscale computational and in silico analyses
- Provenance-Associated Confounding in Cross-Collection Comparisons of Urease Inhibitors: A Quantified Reference Scale and a Domain-Aware Alternative
BibTeX
@article{zhang2026silico,
title = {{In silico prioritization of potential matrix metalloproteinase-13 inhibitors for cartilage degeneration in knee injury-associated osteoarthritis.}},
author = {Aijuan Zhang and Hongmei Chen and Na Song and Juanjuan Zhuang and Baochai Chen and Xiuying Lin and Shuang Jin and Chen Chen},
journal = {BMC biotechnology},
year = {2026},
month = jul,
doi = {10.1186/s12896-026-01200-7},
url = {https://europepmc.org/article/MED/42894143},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - In silico prioritization of potential matrix metalloproteinase-13 inhibitors for cartilage degeneration in knee injury-associated osteoarthritis.
AU - Aijuan Zhang
AU - Hongmei Chen
AU - Na Song
AU - Juanjuan Zhuang
AU - Baochai Chen
AU - Xiuying Lin
AU - Shuang Jin
AU - Chen Chen
PY - 2026
DA - 2026/07/01
JO - BMC biotechnology
DO - 10.1186/s12896-026-01200-7
UR - https://europepmc.org/article/MED/42894143
AB - Knee trauma is an important risk factor for post-traumatic osteoarthritis (PTOA), a progressive joint disease characterized by articular cartilage degeneration and limited disease-modifying treatment options. Matrix metalloproteinase-13 (MMP-13/collagenase-3) contributes to cartilage extracellular matrix degradation through cleavage of type II collagen, making it a relevant molecular target for cartilage-protective drug discovery. This study aimed to identify and prioritize potential small-molecule MMP-13 inhibitors using an integrated in silico workflow. The workflow included MMP-13 sequence retrieval, structural characterization, pharmacophore-based screening, molecular docking, ADMET/toxicity prediction, protein-ligand interaction analysis, protein-protein interaction and co-expression network analysis, and 100 ns molecular dynamics simulation. Among the screened compounds, P4C-BM was prioritized as an early-stage computational lead candidate based on its combined docking score, predicted ADMET profile, interaction pattern, and molecular dynamics stability. However, the findings are preliminary and computational only. The present study does not experimentally demonstrate direct MMP-13 inhibition, selectivity against other MMP family members, cartilage repair, clinical efficacy, or synergy with platelet-rich plasma, physiotherapy, or other treatment modalities. Among the screened compounds, P4C-BM was prioritized as an early-stage computational lead candidate based on its combined docking score, predicted ADMET profile, interaction pattern, and molecular dynamics stability. However, the findings are preliminary and computational only. The present study does not experimentally demonstrate direct MMP-13 inhibition, selectivity against other MMP family members, cartilage protection, cartilage repair, disease modification, or clinical efficacy. Therefore, P4C-BM should be regarded only as a candidate for further experimental validation in enzymatic assays, chondrocyte models, cartilage explant studies, and in vivo osteoarthritis or post-traumatic osteoarthritis models. No practice-related or treatment recommendations can be made from the present data.
SN - 1472-6750
ER -